Pennitracin MD 50G® now approved for the prevention of mortality caused by necrotic enteritis

WILMINGTON, N.C. [May 6, 2022] On April 28th the FDA approved Pennitracin MD 50G® (bacitracin Type A medicated article) for the prevention of mortality caused by necrotic enteritis associated with Clostridium perfringens in broiler and replacement chickens. Necrotic enteritis is a major enteric poultry disease that has a detrimental effect on profitability. This new claim, along with the recent Pennitracin MD 50G® combination approvals with Maxiban® (narasin and nicarbazin) and Coban® (monensin), represent Pharmgate’s ongoing commitment to invest in solutions for flock and herd health and productivity.

In addition to the new necrotic enteritis claim, Pennitracin MD 50G® is approved for increased rate of weight gain and improved feed efficiency in poultry and for the reduction in the number of liver abscesses in cattle. Bacitracin is not considered a medically important antimicrobial in humans, so a VFD is not required for use. Bluebird labeling with this updated claim can be found at and on the FDA Animal Drug website:

Pharmgate Animal Health provides the livestock and poultry industry with a proven portfolio of technically supported, high-quality products that are the foundation of custom herd and flock health protocols. Founded in 2008, the company is headquartered in Wilmington, North Carolina, with FDA approved pharmaceutical production facilities in Omaha, Nebraska, and vaccine research and manufacturing operations in St. Paul, Minnesota. To learn more about Pharmgate Animal Health, or to find a local representative, visit